Venom Immunotherapy: Questions and Controversies

Area of Science:

• Allergy and Immunology
• Clinical Toxicology

Background:

• Venom immunotherapy (VIT) remains a subject of ongoing research and clinical debate.
• Identifying risk factors for severe sting anaphylaxis is crucial for guiding treatment decisions.

Purpose of the Study:

• To review current understanding and controversies surrounding venom immunotherapy.
• To highlight risk factors, treatment strategies, and management decisions in VIT.

Main Methods:

• Review of existing literature and clinical consensus on venom immunotherapy.
• Analysis of risk factors for severe reactions and efficacy of different treatment approaches.

Main Results:

• Premedication, rush VIT, and omalizumab effectively manage recurrent systemic reactions.
• Maintenance doses of VIT are sufficient for children, while high-risk patients may require higher doses.
• The perceived risk of beta-blockers and ACE inhibitors during VIT is now considered small.

Conclusions:

• The decision to discontinue VIT after five years should be based on identified risk factors, not solely on diagnostic tests.
• Risk stratification is key for personalized venom immunotherapy protocols.